MedTrace Logo

Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

NCT05410938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2023-07-10

No results posted yet for this study

Summary

The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.

Conditions

  • Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer

Interventions

DRUG

Chemotherapy

Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410938 on ClinicalTrials.gov